132 related articles for article (PubMed ID: 1842169)
41. Looking beyond 5-HT(3) receptors: a review of the wider role of serotonin in the pharmacology of nausea and vomiting.
Johnston KD; Lu Z; Rudd JA
Eur J Pharmacol; 2014 Jan; 722():13-25. PubMed ID: 24189639
[TBL] [Abstract][Full Text] [Related]
42. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists.
Wolf H
Scand J Rheumatol Suppl; 2000; 113():37-45. PubMed ID: 11028830
[TBL] [Abstract][Full Text] [Related]
43. Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy.
Ward MB; Kotasek D; McKinnon RA
Pharmacogenomics; 2008 Aug; 9(8):1027-33. PubMed ID: 18681779
[TBL] [Abstract][Full Text] [Related]
44. Serotonergic mediation of vomiting.
Gale JD
J Pediatr Gastroenterol Nutr; 1995; 21 Suppl 1():S22-8. PubMed ID: 8708863
[TBL] [Abstract][Full Text] [Related]
45. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret.
Hawthorn J; Ostler KJ; Andrews PL
Q J Exp Physiol; 1988 Jan; 73(1):7-21. PubMed ID: 3347698
[TBL] [Abstract][Full Text] [Related]
46. Emerging differences between 5-HT3 receptor antagonists.
Marr HE; Davey PT; Bartlett AJ
Anticancer Drugs; 1991 Dec; 2(6):513-8. PubMed ID: 1806029
[TBL] [Abstract][Full Text] [Related]
47. Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors.
Hamik A; Peroutka SJ
Cancer Chemother Pharmacol; 1989; 24(5):307-10. PubMed ID: 2527092
[TBL] [Abstract][Full Text] [Related]
48. The ups and downs of novel antiemetic drugs, part 2: an illustration.
Stahl SM
J Clin Psychiatry; 2003 Jun; 64(6):626-7. PubMed ID: 12823074
[TBL] [Abstract][Full Text] [Related]
49. Metoclopramide also acts at serotonin receptors.
Murphy E
Anaesth Intensive Care; 2007 Jun; 35(3):447. PubMed ID: 17591146
[No Abstract] [Full Text] [Related]
50. The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action.
Andrews PL; Bhandari P
Eur J Cancer; 1993; 29A Suppl 1():S11-6. PubMed ID: 8427719
[No Abstract] [Full Text] [Related]
51. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.
Sanger GJ; Andrews PLR
Front Pharmacol; 2018; 9():913. PubMed ID: 30233361
[TBL] [Abstract][Full Text] [Related]
52. Type A Trichothecene Diacetoxyscirpenol-Induced Emesis Corresponds to Secretion of Peptide YY and Serotonin in Mink.
Wu Q; Kuca K; Nepovimova E; Wu W
Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32630472
[TBL] [Abstract][Full Text] [Related]
53. 5-HT3 receptors: pharmacologic and therapeutic aspects.
Gyermek L
J Clin Pharmacol; 1995 Sep; 35(9):845-55. PubMed ID: 8786244
[TBL] [Abstract][Full Text] [Related]
54. 5-HT3 receptor antagonists and migraine therapy.
Ferrari MD
J Neurol; 1991; 238 Suppl 1():S53-6. PubMed ID: 2045832
[TBL] [Abstract][Full Text] [Related]
55. Antagonism of the 5-HT(3) receptor does not alter isoflurane MAC in rats.
Rampil IJ; Laster MJ; Eger EI
Anesthesiology; 2001 Aug; 95(2):562-4. PubMed ID: 11506137
[No Abstract] [Full Text] [Related]
56. Effects of propofol on ipecacuanha-induced nausea and vomiting.
Hammas B; Hvarfner A; Thörn SE; Wattwil M
Acta Anaesthesiol Scand; 1998 Apr; 42(4):447-51. PubMed ID: 9563865
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism.
Miner WD; Sanger GJ
Br J Pharmacol; 1986 Jul; 88(3):497-9. PubMed ID: 3742146
[TBL] [Abstract][Full Text] [Related]
58. Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies.
Andrews PL; Naylor RJ; Joss RA
Support Care Cancer; 1998 May; 6(3):197-203. PubMed ID: 9629870
[TBL] [Abstract][Full Text] [Related]
59. A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.
Cox EH; Veyrat-Follet C; Beal SL; Fuseau E; Kenkare S; Sheiner LB
J Pharmacokinet Biopharm; 1999 Dec; 27(6):625-44. PubMed ID: 11153449
[TBL] [Abstract][Full Text] [Related]
60. Antiemetic effects of sclareol, possibly through 5-HT
Bappi MH; Prottay AAS; Al-Khafaji K; Akbor MS; Hossain MK; Islam MS; Asha AI; Medeiros CR; Tahim CM; Lucetti ECP; Coutinho HDM; Kamli H; Islam MT
Food Chem Toxicol; 2023 Nov; 181():114068. PubMed ID: 37863383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
